Columbia Wanger Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Columbia Wanger Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-402,500	Closed	-$42M	–	204
2015 Q1	$42M	Sell	402,500 -75,200	-16%	-$7.62M	0.23%	153
2014 Q4	$46.3M	Sell	477,700 -76,300	-14%	-$7.07M	0.23%	147
2014 Q3	$43.3M	Sell	554,000 -230,500	-29%	-$14.9M	0.2%	168
2014 Q2	$49.6M	Sell	784,500 -118,264	-13%	-$7.03M	0.2%	170
2014 Q1	$60.6M	Sell	902,764 -1,007,236	-53%	-$78M	0.24%	145
2013 Q4	$123M	Buy	1,910,000 +595,144	+45%	+$35.5M	0.47%	66
2013 Q3	$84.2M	Buy	1,314,856 +216,856	+20%	+$10.8M	0.34%	103
2013 Q2	$34M	Buy	+1,098,000	New	+$29.2M	0.15%	202

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Columbia Wanger Asset Management's ALNY Position: Q2 2015 in Review

Columbia Wanger Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2015, closing a stake of 402,500 shares — an estimated $42M sold.

Columbia Wanger Asset Management first reported a position in ALNY in Q2 2013 and held it in 8 quarters. The position peaked at $123M in Q4 2013. 277 funds tracked by Wall St. Rank hold ALNY as of Q2 2015.

Columbia Wanger Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Columbia Wanger Asset Management sold 402,500 Alnylam Pharmaceuticals shares in Q2 2015, an estimated $42M.
Columbia Wanger Asset Management first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 8 quarters.
Columbia Wanger Asset Management's Alnylam Pharmaceuticals position peaked at $123M in Q4 2013.
277 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2015.

Based on Columbia Wanger Asset Management's 13F filing for Q2 2015, filed 13 Aug 2015.